Continuous manufacturing: CDMOs have a big role play in the next few years 12th August 2021
By Doug Hausner, PhD is the Senior Manager for Continuous Manufacturing Business Development at Thermo Fisher Scientific.
Just prior to the opening of CPhI Discover – global pharma’s largest ever virtual gathering – which took place from May 17-28 this year, the Informa/CPhI Discover team spoke with Doug Hausner, Senior Manager Continuous Manufacturing at Thermo Fisher Scientific. In the interview, he presented his views on how continuous manufacturing is still at the start of its adaption curve in the industry, and what lies ahead as expertise transfers from a handful of pharma companies to first mover CDMOs. Looking ahead, Hausner outlines the business case, the regulatory considerations and the role CDMOs can potentially play in helping biotech customers consider continuous approaches for new products.
CPhI Discover: Can we start by asking a contentious question – what is the definition of a continuous process?
Hausner: The definition established by regulators is that essentially a continuous process is any process where material continually enters and leaves the system at the same rate or close to the same rate. So it’s broad, and that enables it to capture as many things as possible under the continuous banner – which I do think is good, as these things are case by case. But, if you zoom out far enough and think about it, you could look at an entire facility as being a continuous process, and there are some batch facilities that operate very efficiently and could try to fit that definition, so I think it really depends on the scale of scrutiny in terms of how you look at these things. But typically, when we talk about a continuous process, we’re referring to a process in which all the steps involved are continuous and it’s integrated. To add a little further complexity, in terms of hybrid systems, there are a lot of things that fall in between batch and what we might think of as continuous, and these are semi-continuous systems. For example – and you don’t see it as much anymore – some of the early lines may have had a batch blender in the middle of them or two of them, and they’re kind of working in sequence in order to enable it to be a continuous process.
CPhI Discover: How far down the journey are we? We have been speaking about the technology for nearly a decade, but there are so many few commercial processes…..
Hausner: Yes, this is a point that I get back to all the time. It is a very slow adoption curve and again, part of this is that the technology is not enabling a different product that people would otherwise make. So, when something new comes in the market, like you see with some of the new large-molecule therapies, it is more likely that companies build new infrastructure, as otherwise they wouldn’t be able to advance. Conversely, the challenge for continuous processing has been that it provides efficiencies, provides greater quality, and we can go through the whole list of things that it provides. But, at the end of the day, it’s still going to be able to make you the same product that you should be able to make in batch.
The other piece that is starting to change – in part due to CDMOs like mine (Thermo Fisher Scientific) – was the business case, certainly in terms of the upfront investment and the traditional way of doing that where it’s linked to a specific product. But often, continuous processing on a single product business case may not be viable.
Excitingly, however, when you talk about something that’s more of a platform technology, it certainly becomes easier.
The other part that goes along with this is that it takes time and other resources: the personnel and having the people within your organization that understand how to do the process development, and understanding how to handle this from a regulatory perspective.
CPhI Discover: Is continuous manufacturing more suitable for API or finished dose or both?
Hausner: I would say it has more applications in finished dose manufacturing, as here it’s relatively straightforward for the same platform to be used for a lot of different products. The challenge with using it in API manufacturing is that for each product, there are often a number of different steps, with greater variance in methodology between products. This means you will probably need to reconfigure the line from product to product, so it may be a little bit more challenging.
What it does enable for APIs is alternative chemistries that you can’t necessarily achieve in batch mode – e.g. for a dangerous reactions. So, in my organization, we consider continuous manufacturing to be a tool in the toolbox for API manufacturing, but for finished product we see it as a platform technology and that is where we can see the most transformative uses.
CPhI Discover: When is the most appropriate time to consider continuous manufacturing in drug development?
Hausner: It’s a discussion that needs to start by phase two, with a target for phase three clinical manufacturing using continuous to go into the commercial filing, as this is where you won’t have any scale-up after that point. So, the rate limiting step becomes the filing and the approval and other aspects in terms of turning on your commercial engine because once the process has been developed on the line, it’s ready to go commercial the next day.
CPhI Discover: What could accelerate adoption at CDMOs, do we need big pharma support to get started?
Well, what I would say is that that’s kind of what’s happening. If you look at my organization, most of the companies that we’re working with at this point in time are big pharma. Big pharma that has had internal continuous manufacturing programmes understand the technology. They understand what is needed and feel more comfortable with programmes that utilize it. But for smaller clients, there is more hesitancy and CDMO experience is going to come into play, they need to trust the CDMO to guide them through.
CPhI Discover: So,what advice would you give to perhaps a customer, an innovator less experienced, a small pharma or biotech?
Hausner: I guess one piece of advice would be come and talk to us and learn what is being offered before you have an imminent need.The problem is that sometimes the innovator wants to look at continuous, but it’s fairly late in the game and so if they’re already in phase three and are ready to go to commercial, it’s going to be very difficult to re-examine the process without affecting the product’s launch.
So, it’s good to learn early about what is being offered as well as the team’s experience and the regulatory support that can be offered.
Clients often have a number of things in the pipelineand I’ve heard clients say, “We know we’re going to be doing continuous in the future, the question is when?” so the question is, is this the right product? Is this the right time? Is this the right investment for me to make given where my organization is and what I need to do commercially? So there are a lot of factors that go into it.
In terms of what could accelerate adoption at CDMOs, I think we can demonstrate the commercial capability and viability of continuous manufacturing.So, for example, right now we’re working with a number of clients that have products in phase three. Once they get to the commercial stage, I think that will really help to allow other people to say, “okay, this is a technology that I can use without having to make the upfront investment by working with a CDMO.” So, CDMOs that have demonstrated that they can work with other customers and take them through the process from early-stage development all the way through to filing and commercial manufacturing will enable further adoption. We have a large role play in the next few years in helping deliver much wider adoption.